GSK, Genmab Refocus Ofatumumab Development Efforts

GlaxoSmithKline and Genmab have decided to refocus the development program for ofatumumab in autoimmune indications.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Genmab have decided to refocus the development program for ofatumumab in autoimmune indications. GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications and will stop further development on the intravenous administration in autoimmune disease. Based on the positive results from the Phase I/II study in multiple sclerosis (MS), GSK plans to begin a Phase IIB dose ranging study in MS using the subcutaneous administration of the ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters